Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
Recruiting · NCT03975231 · Registry updated 2026-04-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, thyroid gland undifferentiated (anaplastic) carcinoma | Recruiting | Phase 1 | 2026-04-08 | NCT03975231 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| City of Hope Medical Center | 347 |
| National Cancer Institute (NCI) | 3015 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope Medical Center | Duarte | United States | 313 |
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 548 |
| Univ of Texas-M.D. Anderson Cancer Center | Houston | United States | 1 |